caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1790793271

Jose LeisMD

PRACTICEMAYO CLINIC ARIZONASee all providers at this practice →
Hematopoietic Cell Transplantation and Cellular TherapyScottsdale, AZI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
REFERRAL NETWORK

Where Jose Leis's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 13 inbound referrers · 0 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
MAYO CLINIC ARIZONA1872,012
Mayo Collaborative Services, Inc
Clinical Laboratory · Rochester, MN
66294
Ryan Robetorye
Pathology · Scottsdale, AZ
2671
Katalin Kelemen
Pathology · Scottsdale, AZ
2165
Prasad Panse
Diagnostic Radiology · Scottsdale, AZ
1656
Ameet Patel
Diagnostic Radiology · Scottsdale, AZ
1431
Kelley Kennedy
Internal Medicine · Scottsdale, AZ
1349
REEDER, CRAIG1338
Clinton Wellnitz
Diagnostic Radiology · Scottsdale, AZ
1334
CHIVERS, F1330
OLSEN, JANE12110
Frederick Chen
Diagnostic Radiology · Scottsdale, AZ
1234
Refers patients to
Outbound — where patients go next
No outbound pairs above the suppression threshold.
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
PRESCRIBING · PART D · 2024
Total Rx claims
436
Beneficiaries
—
Total drug cost
$2.9M
Distinct drugs
12
Brand share
58.7%
Top prescribed drugs
Acyclovir111 claims
Sulfamethoxazole/Trimethoprim61 claims
Ibrutinib54 claims
Zanubrutinib37 claims
Venetoclax36 claims
QUALITY · MIPS · 2024
Final MIPS score
86.5
Quality
78.3
Cost
76.6
Improvement activities
40.0
Promoting interop.
100.0
Payment adjustment
0.48%
Group
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
No data available for this provider in 2024.
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
1,051
Unique beneficiaries
—
Total services
19,200
Distinct HCPCS
29
Medicare payment
$585K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 6 Hematopoietic Cell Transplantation and Cellular Therapy providers in AZ — below median (cohort median 61,518).